@article{JTD1401,
author = {Konstantinos Zarogoulidis and Paul Zarogoulidis and Kaid Darwiche and Efimia Boutsikou and Nikolaos Machairiotis and Kosmas Tsakiridis and Nikolaos Katsikogiannis and Ioanna Kougioumtzi and Ilias Karapantzos and Haidong Huang and Dionysios Spyratos},
title = {Treatment of non-small cell lung cancer (NSCLC)},
journal = {Journal of Thoracic Disease},
volume = {5},
number = {Suppl 4},
year = {2013},
keywords = {},
abstract = {Radical surgery is the standard of care for fit stage I non-small cell lung cancer (NSCLC) patients. Adjuvant treatment should be offered only as part of an investigation trial. Stage II and IIIA adjuvant cisplatin-based chemotherapy remains the gold standard for completely resected NSCLC tumors. Additionally radiotherapy should be offered in patients with N2 lymph nodes. In advanced stage IIIB/IV or inoperable NSCLC pts, a multidisciplinary treatment should be offered consisted of 4 cycles of cisplatin-based chemotherapy plus a 3rd generation cytotoxic agent or a cytostatic (anti-EGFR, anti-VEGFR) drug.},
issn = {2077-6624}, url = {https://jtd.amegroups.org/article/view/1401}
}